Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16304)	10/3/2003 4:01:05 PM
From: Cacaito	Respond to of 17367

Blue, explain to me this: either the Rituxan Royalty buyers were geniuses giving $17M for 100% profit per year for 20 years... ...or xomeone was idiot enough to sell same Royies to put it in the same kind of trial that your links are suggesting so good !!! You know that was the trauma trial, exactly what you are suggesting so great. By the way, I am sure you remember that during the trauma trial bpi was not able to protect against infections, forget inflammation tough part, BUGS were not prevented by the bpi stuff.

To: Bluegreen who wrote (16304)	10/3/2003 4:08:25 PM
From: Cacaito	Respond to of 17367

Blue what do you think of this: "XOMA recorded revenue of $17 million related to the assignment of certain anti-CD20 antibody patents and royalty rights to Pharmaceutical Partners, LLC. XOMA previously licensed this technology exclusively to Genentech, Inc. (NYSE: GNE), who in turn sublicensed it to IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) for use in the recently approved Rituxan™ product. "This innovative transaction adds another product to our portfolio while enabling XOMA to realize significant cash to fund its core development programs," said Dave Madden of Pharmaceutical Partners. His partner Pablo Legorreta added, "Pharmaceutical Partners was created to invest in royalty interests in pharmaceutical products, and as in the XOMA transaction, we are providing non-recourse, non-dilutive financing in exchange for assuming the risk of the royalty stream on a specific product." "An important part of our business strategy has been to realize value from our non-core technologies to fund development of our BPI product platform," said Jack Castello, chairman, president and CEO of XOMA." he called that INNOVATIVE, I call that rotten MACKERELLE brilliant under the moonlight but STINKY !!!